Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors (ACEi) alone changes micro‐ to macroalbuminuria Median compared with ACEi plus angiotensin receptor blockers (very low certainty).
1 finding from 1 review
Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in micro‐ to normoalbuminuria Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Transplant or graft survival · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes transplant or graft survival compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
Delayed graft function · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes delayed graft function Time frame: 1 to 3 years compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
HbA1c (%) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
FBG (mmol/L) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Kidney function markers · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Death: unknown time frame · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes death (any cause) Time frame: 1 to 5 years compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin receptor blockers may leads to lower doubling of SCr Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal myocardial infarction Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease
Angiotensin receptor blockers may leads to lower micro‐ to macroalbuminuria Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease
It is very uncertain whether angiotensin receptor blockers changes micro‐ to normoalbuminuria Median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in cardiovascular death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Death (any cause) · adults with early (stage 1 to 3) non‐diabetic CKD
1 finding from 1 review
Cardiovascular events · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
It is very uncertain whether angiotensin receptor blockers changes adverse events (number reporting an adverse event) compared with placebo (very low certainty).
1 finding from 1 review